Neu­ro­science drug de­vel­op­er Neumo­ra Ther­a­peu­tics re­leased high­ly an­tic­i­pat­ed re­sults from the first of three Phase 3 tri­als for its ex­per­i­men­tal ma­jor … ...

The biotech reported data from KOASTAL-1, the first of three phase 3 trials of navacaprant in major depressive disorder. Investigators randomized 383 people to receive the oral kappa opioid ...

Despite their potential, however, the magnetic phase diagram of these materials remains largely unexplored. To uncover more, a team of researchers, led by Professor Ryuji Tamura from the ...